Baiyunshan Hanfang Wins China Patent Excellence Award, Demonstrating Its Internationalized Innovative Research Capabilities

Recently, the 20th China Patent Awards Ceremony, co-hosted by the National Intellectual Property Administration and the World Intellectual Property Organization, was held in Beijing. Baiyunshan Hanfang’s innovative patent for technological advancement, “A Method for Preparing Injectable Egg Yolk Phosphatidylcholine” (Patent No.: ZL201410841267.3), was awarded the 20th China Patent Excellence Award, emerging as a rising star on the stage of the China Patent Awards.

Empowering Traditional Chinese Medicine with Technology, Safeguarding Health with Artisanal Dedication—[Baiyunshan Hanfang’s] Journey Toward a Strong Pharmaceutical Nation

Medicine is the core industry that safeguards human life and health; innovation is the inexhaustible driving force behind the development of the pharmaceutical sector. Amid the rapid transformation sweeping the global pharmaceutical industry, [Company Name] has consistently upheld “carrying forward the essence while staying true to fundamentals and embracing innovation” as its original aspiration and “achieving technological self-reliance and strength” as its mission. The company has deeply cultivated the field of pharmaceutical manufacturing, continuously breaking new ground in areas such as the domestic production of high-end pharmaceutical excipients, the modernization of traditional Chinese medicine, and the expansion into international markets, thereby forging a path of high-quality pharmaceutical development that combines Chinese characteristics with a global perspective.

The Party Committee of Baiyunshan Hanfang Organizes and Convenes the 2025 Special Organizational Life Meeting on Case-Based Rectification

Recently, the Party Committee of Baiyunshan Hanfang, closely adhering to the guidance of Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era, organized its six subordinate Party branches to hold high-quality special organizational life meetings for 2025, focusing on case-based rectification.

Baiyunshan Hanfang has completed its shareholding system reform and officially changed its name!

Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. has successfully completed its shareholding reform and was officially renamed Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. on March 27, 2026. This rebranding is a significant step in the company’s deepening state-owned enterprise reform and in perfecting its modern corporate governance system, marking a crucial milestone on its path toward market-oriented development and standardized management. Moving forward under its new identity, the company will embark on a new journey of high-quality growth, continuing to focus on the biopharmaceutical and health industries while fulfilling its corporate mission and social responsibilities.